US20100003746A1 - Production of Lentiviral Vectors - Google Patents
Production of Lentiviral Vectors Download PDFInfo
- Publication number
- US20100003746A1 US20100003746A1 US12/522,646 US52264608A US2010003746A1 US 20100003746 A1 US20100003746 A1 US 20100003746A1 US 52264608 A US52264608 A US 52264608A US 2010003746 A1 US2010003746 A1 US 2010003746A1
- Authority
- US
- United States
- Prior art keywords
- lentivirus
- baculovirus
- cells
- bac
- baculoviruses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Definitions
- the invention relates to methods for the production of lentiviral vectors.
- Lentiviruses such as Human Immunodeficiency Virus I
- Lentiviruses are promising tools for gene therapy due to their ability to transduce and integrate into the genome of both dividing and non-dividing cells.
- the production of replication-defective lentiviral vectors for large-scale clinical use is challenging.
- Lentiviral vectors are normally produced by cotransfecting 293T human embryonic kidney cells with several different plasmid constructs. The first clinical lentiviral vector production was based on a two-plasmid system (Lu et al., 2004). To further improve the safety of the system, lentivirus genome can be separated into four plasmids.
- the plasmids are a self-inactivating transfer vector; a packaging plasmid containing gag-pol; a rev plasmid; and an envelope glycoprotein plasmid which usually encodes vesicular stomatitis virus glycoprotein G (VSV-G).
- VSV-G vesicular stomatitis virus glycoprotein G
- VSV-G fusogenic envelope protein
- Lentiviral vectors can also be pseudotyped by various viral surface proteins.
- the most commonly used is the envelope glycoprotein G of the vesicular stomatitis virus (VSV-G).
- VSV-G vesicular stomatitis virus
- various different envelope glycoproteins such as those from gamma-retroviruses (e.g. feline endogenous retrovirus RD114 env, modified gibbon ape leukaemia virus GaIV, moloney murine leukaemia virus MLV), alphaviruses, lyssaviruses or baculoviruses had also been shown to pseudotype lentiviral vectors.
- Pseudotyping broadens the transduction range of lentiviruses, and long-term transgene expression has been obtained in many different cells and tissues (Delenda, 2004). Pseudotyping also strengthens fragile lentiviruses and enables concentration to high titers by ultracentrifugation.
- Baculoviruses possess several advantages for gene delivery applications. They have a large insert capacity (>100 kb) and are capable of transducing most mammalian cell lines, even in large-scale suspension cell cultures in serum-free conditions (Scott et al., 2007). In addition, baculoviruses are easy to produce in large-scale and high titers, and they present few safety problems as they are not able to replicate in mammalian cells. Cytotoxicity is very rarely detected, even with high Multiplicity of Infection (MOI).
- MOI Multiplicity of Infection
- Baculoviruses have been used for a large-scale protein production in insect cells and for the production of viral-like particles (VLP), such as hepatitis VLP. Intact viruses have also been produced using hybrid baculoviruses. Baculovirus-mediated production of recombinant influenza viruses, adenoviruses (Cheshenko et al, 2001) and AAV (Auang et al, 2007) in mammalian cells has also been described.
- VLP viral-like particles
- Intact viruses have also been produced using hybrid baculoviruses.
- Baculovirus-mediated production of recombinant influenza viruses, adenoviruses (Cheshenko et al, 2001) and AAV (Auang et al, 2007) in mammalian cells has also been described.
- a method of generating a lentivirus vector comprises cloning each of a lentivirus transfer construct, gag, pol, an envelope protein and rev respectively into the same or different baculoviruses, and transducing a producer cell with the or each baculovirus.
- FIG. 1 is a schematic diagram and shows cloned baculovirus donor plasmids, BAC-transfer, BAC-gag-pol, BAC-VSVg and BAC-rev.
- FIG. 2 is a schematic diagram of baculovirus-mediated lentivirus production.
- the baculovirus(es) must comprise a lentivirus transfer construct, gag, pol, a suitable envelope protein and rev.
- lentivirus transfer construct will be known to those skilled in the art.
- a lentivirus transfer construct is a source of lentiviral RNA genome/lentiviral vector RNA and transgene cassette.
- lentivirus transfer construct is LV1-GFP.
- Methods for producing lentivirus transfer constructs will also be known to those skilled in the art.
- envelope protein will be known to those skilled in the art.
- An envelope protein is a protein that protects the nucleic acid of a virus.
- An example of envelope protein suitable for use, in the invention is VSV-G.
- producer cell will be known to those skilled in the art.
- Examples of producer cells suitable for use in the invention are 293T, HepG2, CHO, BHK, Sf9, Sf21, 293, BTI-Tn 5 B 1-4, COS, NIH/3T3, Vero, NSO or PerC6 cells.
- the produced cells may then be cultured as adherent or in suspension.
- all the elements needed for the production of functional lentiviruses according to the invention are cloned into three different baculoviruses. More preferably, they are cloned into two different baculoviruses, and most preferably, they are cloned into one single baculovirus. This may be achieved by combining the features of BAC-transfer, BAC-gag-pol, BAC-VSVg and BAC-rev into a single baculovirus.
- baculoviruses Four recombinant baculoviruses BAC-transfer, BAC-gag-pol, BAC-VSVg and BAC-rev, derived from Autographa califomica multicapsid nucleopolyhedrovirus (AcMNPV) have been constructed. They encode all the elements needed for lentivirus vector generation in mammalian cells. By transducting 293T cells with these baculoviruses, a functional lentivirus has been produced.
- AcMNPV Autographa califomica multicapsid nucleopolyhedrovirus
- Baculovirus technology is an attractive option for scalable virus production due to ease of production, concentration of baculovirses, efficient transduction of suspension mammalian cells in serum-free conditions and safety.
- the lentiviral vector may also be produced with the baculovirus encoding or displaying viral protein rev, tat, net, vit or vpu, by, but are not limited to, fusing the viral protein to a baculovirus protein.
- the baculovirus protein may be the major envelope protein gp64 or the capsid proteins, vp39 and p24.
- the resulting lentiviruses may be pseutotyped with heterologous proteins or other ligands, such as VSV-g, gp64, avidin, streptavidin or biotin.
- baculovirus donor vector pFastBac1 All the necessary elements for the production of 3 rd generation lentiviral vectors in mammalian cells were subcloned into baculovirus donor vector pFastBac1 to construct four recombinant baculoviruses, BAC-transfer, BAC-gag-pol, BAC-VSVg and BAC-rev, derived from Autographa californica multipled nucleopolyhedrovirus (AcMNPV) ( FIG. 1 ).
- AcMNPV Autographa californica multipled nucleopolyhedrovirus
- a polylinker containing multiple cloning sites (PmlI/NheI/PstI/SalI/AflII/PacI/SpeI/MluI/Pmel/EcoRI/Apal/Swal/AscI) was cloned into the unique AvrII site of pFastBac1.
- the sequence of the polylinker was 5′ CACGTGGCTAGCCTGCAGGTCGACCTTAAGTTAATTAAACTAGTACGCGTGT TTAAACGAATTCGGGCCCATTTAAATGGCGCGCC-3′ (SEQ ID No: 1).
- the donor vector also contained the red fluorescent protein marker gene (DsRed) under the control of a polyhedrin promoter for convenient baculovirus titer determination.
- LV1-GFP ⁇ NGFP from plasmid LV-hPGK- ⁇ NGFP-WPRE-SIN (Makinen, 2006) was replaced by GFP.
- the GFP marker gene is driven by the phosphoglycerate kinase (PGK) promoter.
- the pBAC-transfer vector was constructed by subcloning the relevant sequence from LV1-GFP into the pFastBac1 donor vector polylinker in two stages.
- LV1-GFP was digested with BsrBI and AscI and subcloned into SwaI/AscI-site of the donor vector polylinker.
- the second part of the sequence was cloned by digesting LV1-GFP with AscI and AvrII and inserting the fragment into the AscI and AvrII sites of the modified pFastBac1-plasmid.
- the packaging construct (pBAC-gag-pol) expressing gag and pol driven by CMV promoter was derived from the plasmid pMDLg/pRRE (Follenzi and Naldini, 2002) by ApaLI digestion and subcloned into the SmiI-site of the donor vector. Prior to ligation ApaLI ends were blunted with T4 DNA Polymerase (Finnzymes, Helsinki, Finland).
- VSV-G envelope construct from the plasmid pCMV-VSVG was subcloned into the pFastBac1 vector in two stages.
- pCMV-VSVG was digested with NotI and blunted using T4 DNA Polymerase prior to digestion with EcoRI. This fragment was subcloned to the SmiI/EcoRI-site of the polylinker.
- the second part of the sequence was digested from PCMV-VSVG with EcoRI and subcloned into the polylinker EcoRI site.
- Rev cDNA was obtained by polymerase chain reaction (PCR) from the plasmid pRSV-REV (Dull et al, 1998) using forward and reverse primers.
- the forward primer is 5′ CGAAGGAATTCGTCGCCACCATGGCAGGAAGAAGCGGA-3′ (SEQ ID No: 2).
- the sequence for nucleotides 1-18 of the rev gene is in bold, the Kozak concensus sequence is in italic, and the EcoRI site underlined.
- the reverse primer is 5′ AGCTAGCTAGCGTATTCTCCTGACTCCAATATTGT-3′ (SEQ ID No: 3).
- the sequence for nucleotides 349-325 of the rev gene is in bold and the NheI site is underlined.
- the amplified PCR product was digested with EcoRI and NheI, purifed using a Wizard Clean up kit (Promega, Madison, Wis., USA), and subcloned into the EcoRI/NheI-site of the pFastBac1 polylinker to form pBAC-rev.
- Rev cDNA was under the control of the CMV promoter which was previously subcloned as a NruI/EcoRI fragment from the pcDNA3 vector (Invitrogen) into the SwaI/EcoRI-site of the pFastBac1 polylinker.
- 293T cells were plated 24 h before transduction.
- Cells were cultured in Dulbecco's Modified Eagles Medium (DMEM) or RPMI 1640 both supplemented with 10% fetal bovine serum (FBS).
- DMEM Dulbecco's Modified Eagles Medium
- FBS fetal bovine serum
- Transduction was performed with varying multiplicity of infection (MOI) between 50 and 1000 pfu per cell in either serum-free or serum supplemented DMEM or RPMI. After 4 h incubation in serum-free medium or 18 h in serum supplemented DMEM or RPMI at 37° C. the cells were washed and medium was changed. The cell supernatant containing lentiviruses was collected 48 h post transduction and centrifuged at 1500 rpm for 10 min at room temperature.
- MOI multiplicity of infection
- Lentiviruses were also prepared by conventional four plasmid transient transfection method in 293T cells (Follenzi and Naldini, 2002). To improve the attachment of the cells to the bottom of the plates, the plates were coated with poly-L-lysine, according to the manufacturer's instructions.
- Transforming units of lentiviruses were determined by analyzing the number of virus particles able to transduce HeLa cells. On day one Hela cells were seeded in 6-well plates at 1 ⁇ 10 5 or in 96-well plates at 5 ⁇ 10 3 cells per well. The lentivirus transduction was carried out on day two with serial dilution. On day five the cells were visualized with fluorescent microscopy and analyzed by flow cytometry to reveal the percentage of cells which were transduced by GFP expressing lentiviruses. Titers were calculated as described in Follenzi and Naldini, 2002.
- HeLa cells (5 ⁇ 10 3 ) were seeded on the 96 well plates, transduced next day with baculovirus-produced lentiviruses and cells were cultured up to 6 weeks. GFP expression was monitored weekly by flow cytometer. As an additional control, Hela cells were also transduced with baculovirus BAC-transfer expressing GFP and the expression was monitored in a similar way.
- the amount of lentiviral capsid protein p24 was determined by p24 ELISA kit (NENTM Life Science Products HIV-1 p24 ELISA). Testing of the replication competent lentiviruses (RCL) was done by p24 ELISA determination from the cell culture supernatants. HeLa cells were transduced with lentivirus and the transduction efficiency was monitored by flow cytometer. Cells were cultured for four weeks, supernatants were collected and the concentration of p24 in the supernatants was measured repeatedly as a marker of RCL. This was further confirmed by transducing naive HeLa cells with collected supernatants and GFP expression was monitored by fluorescent microscopy and flow cytometer.
- the key 3 rd generation elements were cloned into four baculoviruses.
- the baculovirus plasmid constructs were verified by restriction analysis and four baculoviruses were generated in Insect cells.
- immunoblot analysis was conducted on each batch, with anti-gp64 against major envelope protein of baculovirus. End point titer determination (IU/ml) for concentrated baculoviruses was done in insect cells. High titers (>1010 IU/ml) were measured for all produced viruses and used to control MOI in lentivirus production.
- Lentiviruses were produced by transduction of 293T cells with four baculoviruses. Transduction was performed using different mediums and incubation times. The transduction efficacy was monitored 20 h after the transduction by fluorescent microscopy. Lentivirus containing supernatants were collected 48 h after the transduction and titers were determined in HeLa cells as transducing units (TU/ml).
- baculoviruses at MOI 500 each yielded lentivirus titers with an average of 6.0 ⁇ 10 5 TU/ml when transduction was performed 4 h in serum-free conditions.
- Baculovirus concentration at MOI 750 produced higher lentivirus titers with an average of 1.2 ⁇ 10 6 TU/ml.
- a decrease in titer was detected when higher baculovirus concentrations (four baculoviruses at MOI 1000 each) were used.
- Four baculoviruses at MOI 250 yielded the highest titers with an average of 2.5 ⁇ 10 6 TU/ml when baculovirus transduction was performed over night.
- the highest titers were an average of 5.9 ⁇ 10 5 TU/ml already at MOI 50.
- the titers are comparable to those produced with conventional four plasmid transduction method (Follenzi and Naldini, 2002).
- the different ratio of plasmids can influence titers in plasmid transfection.
- the lentivirus titers were 0.64 fold lower than expected.
- BAC-transfer virus was also doubled, to see if higher lentivirus titers could be obtained.
- Titers obtained with the doubled amount of the BAC-transfer were at on an average of 1.4 ⁇ 10 6 TU/ml.
- lentivirus production was performed, omitting one of the baculoviruses (BAC-gag-pol, BAC-Rev or BAC-VSVg) at a time. Collected mediums were used to transduce HeLa cells and the number of GFP positive cells (%) was analyzed four days after the transduction by flow cytometer. No GFP positive cells could be determined in these experiments.
- Residual baculoviruses in the collected lentivirus medium was evaluated by end point tittering and the titer was 0.1-0.5% from the dose used for 293T cell transduction.
- 293T cells were transduced with the BAC-transfer baculovirus only.
- HeLa cells were then transduced with the medium collected similar way than in lentivirus preparation and GFP positive cells were analysed with flow cytometer four days after transduction. No GFP positive cells could be detected.
- Baculovirus vectors do not replicate in vertebrate cells and they cannot integrate into the host genome. Gene expression from these vectors is transient and usually lost in two weeks. However, transgene expression from an integrated lentivirus is relatively stable assuming no silencing of the transgene expression occurs. Baculovirus-produced lentiviruses transduction lead to efficient GFP expression which could still be observed after 43 days post transduction ( FIG. 5A ). Expression was also detected by fluorescent microscopy in HeLa cells at day three Baculovirus-mediated GFP expression at MOI 100 and 1000 (18.7+1.9% and 11.5 ⁇ 0.4% at day three, respectively) was lost 17 days after post transduction.
- Replication-competent lentiviruses were tested by p24 ELISA assay.
- HeLa cells were transduced with lentivirus containing mediums. Transduction efficiencies were verified by flow cytometer. Cells were cultured for four weeks and concentration of p24 in the supernatant was repeatedly measured. An increasing concentration of p24 would indicate an ongoing viral replication, but no such increase was detected. Mediums collected from transduced HeLa cells after 2.5 weeks were further used to transduce naive HeLa cells but no GFP expression was detected neither with fluorescent microscopy nor flow cytometer.
- the lowest baculovirus dose (MOI 50) resulted in the best lentivirus titers. This is in line with the fact that the transduction medium affects baculovirus-mediated gene expression in vertebrate cells.
- the transduction medium affects baculovirus-mediated gene expression in vertebrate cells.
- HeLa cells were transduced and sustained GFP expression was observed for 6 weeks. However, with the control baculovirus the GFP expression was lost in 17 days. If lentivirus generation was performed by omitting either BAC-gag-pol, BAC-Rev or BAC-VSVg, no lentivirus was produced.
- baculoviruses are safe, contamination of the lentivirus preparation with baculoviruses is not desirable.
- the amount of residual baculoviruses in the lentivirus preparations was only 0.1-0.5% of the baculovirus dose used in the simple lentivirus production protocol in which the 293T cells were washed only once after baculovirus transduction.
- the residual baculovirus may be further reduced by simply adding extra washing step(s) or using adequate down-stream purification schema.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Manufacturing & Machinery (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- The invention relates to methods for the production of lentiviral vectors.
- Lentiviruses, such as Human Immunodeficiency Virus I, are promising tools for gene therapy due to their ability to transduce and integrate into the genome of both dividing and non-dividing cells. However, the production of replication-defective lentiviral vectors for large-scale clinical use is challenging. Lentiviral vectors are normally produced by cotransfecting 293T human embryonic kidney cells with several different plasmid constructs. The first clinical lentiviral vector production was based on a two-plasmid system (Lu et al., 2004). To further improve the safety of the system, lentivirus genome can be separated into four plasmids. The plasmids are a self-inactivating transfer vector; a packaging plasmid containing gag-pol; a rev plasmid; and an envelope glycoprotein plasmid which usually encodes vesicular stomatitis virus glycoprotein G (VSV-G). To upscale lentivirus production, the growth of adherent cells has been changed to cell factories. Lentiviral vectors have also been transiently produced in suspension cultures using 3-L bioreactors in serum-free conditions.
- As transient transfection systems for virus production can be problematic and time-consuming, attempts have been made to develop stable large-scale production systems. However, the toxicity of lentiviral protease and the fusogenic envelope protein, VSV-G, has prohibited constitutive vector production. One production method uses inducible packaging cell lines, controlled either by tetracycline- or ecdysone-inducible promoter systems. Other production methods involve replacing the toxic VSV-G protein with less toxic glycoproteins.
- Lentiviral vectors can also be pseudotyped by various viral surface proteins. The most commonly used is the envelope glycoprotein G of the vesicular stomatitis virus (VSV-G). In addition, various different envelope glycoproteins such as those from gamma-retroviruses (e.g. feline endogenous retrovirus RD114 env, modified gibbon ape leukaemia virus GaIV, moloney murine leukaemia virus MLV), alphaviruses, lyssaviruses or baculoviruses had also been shown to pseudotype lentiviral vectors. Pseudotyping broadens the transduction range of lentiviruses, and long-term transgene expression has been obtained in many different cells and tissues (Delenda, 2004). Pseudotyping also strengthens fragile lentiviruses and enables concentration to high titers by ultracentrifugation.
- Baculoviruses possess several advantages for gene delivery applications. They have a large insert capacity (>100 kb) and are capable of transducing most mammalian cell lines, even in large-scale suspension cell cultures in serum-free conditions (Scott et al., 2007). In addition, baculoviruses are easy to produce in large-scale and high titers, and they present few safety problems as they are not able to replicate in mammalian cells. Cytotoxicity is very rarely detected, even with high Multiplicity of Infection (MOI).
- Baculoviruses have been used for a large-scale protein production in insect cells and for the production of viral-like particles (VLP), such as hepatitis VLP. Intact viruses have also been produced using hybrid baculoviruses. Baculovirus-mediated production of recombinant influenza viruses, adenoviruses (Cheshenko et al, 2001) and AAV (Auang et al, 2007) in mammalian cells has also been described.
- According to the present invention, a method of generating a lentivirus vector, comprises cloning each of a lentivirus transfer construct, gag, pol, an envelope protein and rev respectively into the same or different baculoviruses, and transducing a producer cell with the or each baculovirus.
- The following drawings illustrate embodiments of the invention.
-
FIG. 1 is a schematic diagram and shows cloned baculovirus donor plasmids, BAC-transfer, BAC-gag-pol, BAC-VSVg and BAC-rev. -
FIG. 2 is a schematic diagram of baculovirus-mediated lentivirus production. - To perform the method of the invention, the baculovirus(es) must comprise a lentivirus transfer construct, gag, pol, a suitable envelope protein and rev.
- The term “lentivirus transfer construct” will be known to those skilled in the art. A lentivirus transfer construct is a source of lentiviral RNA genome/lentiviral vector RNA and transgene cassette. One example of a lentivirus transfer construct is LV1-GFP. Methods for producing lentivirus transfer constructs will also be known to those skilled in the art.
- The term “envelope protein” will be known to those skilled in the art. An envelope protein is a protein that protects the nucleic acid of a virus. An example of envelope protein suitable for use, in the invention is VSV-G.
- The term “producer cell” will be known to those skilled in the art. Examples of producer cells suitable for use in the invention are 293T, HepG2, CHO, BHK, Sf9, Sf21, 293, BTI-Tn 5 B 1-4, COS, NIH/3T3, Vero, NSO or PerC6 cells. The produced cells may then be cultured as adherent or in suspension.
- Preferably, all the elements needed for the production of functional lentiviruses according to the invention are cloned into three different baculoviruses. More preferably, they are cloned into two different baculoviruses, and most preferably, they are cloned into one single baculovirus. This may be achieved by combining the features of BAC-transfer, BAC-gag-pol, BAC-VSVg and BAC-rev into a single baculovirus.
- Four recombinant baculoviruses BAC-transfer, BAC-gag-pol, BAC-VSVg and BAC-rev, derived from Autographa califomica multicapsid nucleopolyhedrovirus (AcMNPV) have been constructed. They encode all the elements needed for lentivirus vector generation in mammalian cells. By transducting 293T cells with these baculoviruses, a functional lentivirus has been produced.
- Baculovirus technology is an attractive option for scalable virus production due to ease of production, concentration of baculovirses, efficient transduction of suspension mammalian cells in serum-free conditions and safety. The lentiviral vector may also be produced with the baculovirus encoding or displaying viral protein rev, tat, net, vit or vpu, by, but are not limited to, fusing the viral protein to a baculovirus protein. The baculovirus protein may be the major envelope protein gp64 or the capsid proteins, vp39 and p24.
- The resulting lentiviruses may be pseutotyped with heterologous proteins or other ligands, such as VSV-g, gp64, avidin, streptavidin or biotin.
- The following Example illustrates the invention.
- All the necessary elements for the production of 3rd generation lentiviral vectors in mammalian cells were subcloned into baculovirus donor vector pFastBac1 to construct four recombinant baculoviruses, BAC-transfer, BAC-gag-pol, BAC-VSVg and BAC-rev, derived from Autographa californica multipled nucleopolyhedrovirus (AcMNPV) (
FIG. 1 ). First, a polylinker containing multiple cloning sites (PmlI/NheI/PstI/SalI/AflII/PacI/SpeI/MluI/Pmel/EcoRI/Apal/Swal/AscI) was cloned into the unique AvrII site of pFastBac1. The sequence of the polylinker was 5′ CACGTGGCTAGCCTGCAGGTCGACCTTAAGTTAATTAAACTAGTACGCGTGT TTAAACGAATTCGGGCCCATTTAAATGGCGCGCC-3′ (SEQ ID No: 1). The donor vector also contained the red fluorescent protein marker gene (DsRed) under the control of a polyhedrin promoter for convenient baculovirus titer determination. - To generate a third-generation self-inactivating lentivirus transfer construct, (LV1-GFP) ΔNGFP from plasmid LV-hPGK-ΔNGFP-WPRE-SIN (Makinen, 2006) was replaced by GFP. In this construct, the GFP marker gene is driven by the phosphoglycerate kinase (PGK) promoter. The pBAC-transfer vector was constructed by subcloning the relevant sequence from LV1-GFP into the pFastBac1 donor vector polylinker in two stages. To clone the first part of the sequence, LV1-GFP was digested with BsrBI and AscI and subcloned into SwaI/AscI-site of the donor vector polylinker. The second part of the sequence was cloned by digesting LV1-GFP with AscI and AvrII and inserting the fragment into the AscI and AvrII sites of the modified pFastBac1-plasmid.
- The packaging construct (pBAC-gag-pol) expressing gag and pol driven by CMV promoter was derived from the plasmid pMDLg/pRRE (Follenzi and Naldini, 2002) by ApaLI digestion and subcloned into the SmiI-site of the donor vector. Prior to ligation ApaLI ends were blunted with T4 DNA Polymerase (Finnzymes, Helsinki, Finland).
- The VSV-G envelope construct from the plasmid pCMV-VSVG was subcloned into the pFastBac1 vector in two stages. First, pCMV-VSVG was digested with NotI and blunted using T4 DNA Polymerase prior to digestion with EcoRI. This fragment was subcloned to the SmiI/EcoRI-site of the polylinker. The second part of the sequence was digested from PCMV-VSVG with EcoRI and subcloned into the polylinker EcoRI site.
- Rev cDNA was obtained by polymerase chain reaction (PCR) from the plasmid pRSV-REV (Dull et al, 1998) using forward and reverse primers. The forward primer is 5′ CGAAGGAATTCGTCGCCACCATGGCAGGAAGAAGCGGA-3′ (SEQ ID No: 2). The sequence for nucleotides 1-18 of the rev gene is in bold, the Kozak concensus sequence is in italic, and the EcoRI site underlined. The reverse primer is 5′ AGCTAGCTAGCGTATTCTCCTGACTCCAATATTGT-3′ (SEQ ID No: 3). The sequence for nucleotides 349-325 of the rev gene is in bold and the NheI site is underlined. The amplified PCR product was digested with EcoRI and NheI, purifed using a Wizard Clean up kit (Promega, Madison, Wis., USA), and subcloned into the EcoRI/NheI-site of the pFastBac1 polylinker to form pBAC-rev. Rev cDNA was under the control of the CMV promoter which was previously subcloned as a NruI/EcoRI fragment from the pcDNA3 vector (Invitrogen) into the SwaI/EcoRI-site of the pFastBac1 polylinker.
- 293T cells were plated 24 h before transduction. Cells were cultured in Dulbecco's Modified Eagles Medium (DMEM) or RPMI 1640 both supplemented with 10% fetal bovine serum (FBS). Transduction was performed with varying multiplicity of infection (MOI) between 50 and 1000 pfu per cell in either serum-free or serum supplemented DMEM or RPMI. After 4 h incubation in serum-free medium or 18 h in serum supplemented DMEM or RPMI at 37° C. the cells were washed and medium was changed. The cell supernatant containing lentiviruses was collected 48 h post transduction and centrifuged at 1500 rpm for 10 min at room temperature.
- As controls, batches were made where each of the three baculoviruses were missing (BAC-gag-pol, BAC-Rev or BAC-VSVg). Lentiviruses were also prepared by conventional four plasmid transient transfection method in 293T cells (Follenzi and Naldini, 2002). To improve the attachment of the cells to the bottom of the plates, the plates were coated with poly-L-lysine, according to the manufacturer's instructions.
- Transforming units of lentiviruses (TU/ml) were determined by analyzing the number of virus particles able to transduce HeLa cells. On day one Hela cells were seeded in 6-well plates at 1×105 or in 96-well plates at 5×103 cells per well. The lentivirus transduction was carried out on day two with serial dilution. On day five the cells were visualized with fluorescent microscopy and analyzed by flow cytometry to reveal the percentage of cells which were transduced by GFP expressing lentiviruses. Titers were calculated as described in Follenzi and Naldini, 2002.
- HeLa cells (5×103) were seeded on the 96 well plates, transduced next day with baculovirus-produced lentiviruses and cells were cultured up to 6 weeks. GFP expression was monitored weekly by flow cytometer. As an additional control, Hela cells were also transduced with baculovirus BAC-transfer expressing GFP and the expression was monitored in a similar way.
- The amount of lentiviral capsid protein p24 (pg/mi) was determined by p24 ELISA kit (NEN™ Life Science Products HIV-1 p24 ELISA). Testing of the replication competent lentiviruses (RCL) was done by p24 ELISA determination from the cell culture supernatants. HeLa cells were transduced with lentivirus and the transduction efficiency was monitored by flow cytometer. Cells were cultured for four weeks, supernatants were collected and the concentration of p24 in the supernatants was measured repeatedly as a marker of RCL. This was further confirmed by transducing naive HeLa cells with collected supernatants and GFP expression was monitored by fluorescent microscopy and flow cytometer.
- Statistical analyses were performed by GraphPadPrism 4 (GraphPad Software Inc., San Diego, Calif., USA).
- The key 3rd generation elements were cloned into four baculoviruses. The baculovirus plasmid constructs were verified by restriction analysis and four baculoviruses were generated in Insect cells. To monitor consistency of the baculovirus production, immunoblot analysis was conducted on each batch, with anti-gp64 against major envelope protein of baculovirus. End point titer determination (IU/ml) for concentrated baculoviruses was done in insect cells. High titers (>1010 IU/ml) were measured for all produced viruses and used to control MOI in lentivirus production.
- Lentiviruses were produced by transduction of 293T cells with four baculoviruses. Transduction was performed using different mediums and incubation times. The transduction efficacy was monitored 20 h after the transduction by fluorescent microscopy. Lentivirus containing supernatants were collected 48 h after the transduction and titers were determined in HeLa cells as transducing units (TU/ml).
- Four baculoviruses at MOI 500 each yielded lentivirus titers with an average of 6.0×105 TU/ml when transduction was performed 4 h in serum-free conditions. Baculovirus concentration at MOI 750 produced higher lentivirus titers with an average of 1.2×106 TU/ml. A decrease in titer was detected when higher baculovirus concentrations (four baculoviruses at MOI 1000 each) were used. Four baculoviruses at MOI 250 yielded the highest titers with an average of 2.5×106 TU/ml when baculovirus transduction was performed over night. When RPMI medium was used in transduction, the highest titers were an average of 5.9×105 TU/ml already at MOI 50. The titers are comparable to those produced with conventional four plasmid transduction method (Follenzi and Naldini, 2002).
- The different ratio of plasmids can influence titers in plasmid transfection. When the same ratio of baculoviruses as is commonly used with plasmids were used, the lentivirus titers were 0.64 fold lower than expected. BAC-transfer virus was also doubled, to see if higher lentivirus titers could be obtained. However, there was no significant difference in the titers compared to the production with similar doses of baculoviruses. Titers obtained with the doubled amount of the BAC-transfer were at on an average of 1.4×106 TU/ml.
- As negative controls, lentivirus production was performed, omitting one of the baculoviruses (BAC-gag-pol, BAC-Rev or BAC-VSVg) at a time. Collected mediums were used to transduce HeLa cells and the number of GFP positive cells (%) was analyzed four days after the transduction by flow cytometer. No GFP positive cells could be determined in these experiments.
- A frequently used titration method alongside with a biological titer (TU/ml) of lentiviruses measures p24 concentration (pg/ml) by ELISA. The p24 concentrations in the medium were 191±105 ng/ml which corresponds the values for the representative virus preparations. However, p24 concentration does not separate biologically active particles. To compare infectious particles and p24 ratio, both of these parameters were measured from several preparations produced with different amounts or ratios of baculoviruses. The results showed good TU/p24 ratio.
- Residual baculoviruses in the collected lentivirus medium was evaluated by end point tittering and the titer was 0.1-0.5% from the dose used for 293T cell transduction. To confirm that transgene expression was originated from the produced lentivirus, and not from residual baculovirus, 293T cells were transduced with the BAC-transfer baculovirus only. HeLa cells were then transduced with the medium collected similar way than in lentivirus preparation and GFP positive cells were analysed with flow cytometer four days after transduction. No GFP positive cells could be detected.
- Baculovirus vectors do not replicate in vertebrate cells and they cannot integrate into the host genome. Gene expression from these vectors is transient and usually lost in two weeks. However, transgene expression from an integrated lentivirus is relatively stable assuming no silencing of the transgene expression occurs. Baculovirus-produced lentiviruses transduction lead to efficient GFP expression which could still be observed after 43 days post transduction (
FIG. 5A ). Expression was also detected by fluorescent microscopy in HeLa cells at day three Baculovirus-mediated GFP expression at MOI 100 and 1000 (18.7+1.9% and 11.5±0.4% at day three, respectively) was lost 17 days after post transduction. - Replication-competent lentiviruses (RCL) were tested by p24 ELISA assay. HeLa cells were transduced with lentivirus containing mediums. Transduction efficiencies were verified by flow cytometer. Cells were cultured for four weeks and concentration of p24 in the supernatant was repeatedly measured. An increasing concentration of p24 would indicate an ongoing viral replication, but no such increase was detected. Mediums collected from transduced HeLa cells after 2.5 weeks were further used to transduce naive HeLa cells but no GFP expression was detected neither with fluorescent microscopy nor flow cytometer.
- In summary, successful generation of functional lentiviruses using hybrid baculoviruses has been demonstrated. Lentivirus titers produced by baculoviruses were comparable to those produced using the conventional four plasmid transfection method. Good lentivirus titers were achieved when optimal dose of baculoviruses and extended transduction time was used. A decrease in lentivirus titers and cell death was observed when high doses of baculoviruses were used. This may be due to the VSV-G toxicity to production cells. No problems were observed when the VSV-G expressing baculovirus was omitted, keeping the total number of baculovirus particles constant. By replacing the DMEM medium with RPMI1640, the lowest baculovirus dose (MOI 50) resulted in the best lentivirus titers. This is in line with the fact that the transduction medium affects baculovirus-mediated gene expression in vertebrate cells. To confirm the functionality of the generated lentiviruses, HeLa cells were transduced and sustained GFP expression was observed for 6 weeks. However, with the control baculovirus the GFP expression was lost in 17 days. If lentivirus generation was performed by omitting either BAC-gag-pol, BAC-Rev or BAC-VSVg, no lentivirus was produced.
- Although baculoviruses are safe, contamination of the lentivirus preparation with baculoviruses is not desirable. The amount of residual baculoviruses in the lentivirus preparations was only 0.1-0.5% of the baculovirus dose used in the simple lentivirus production protocol in which the 293T cells were washed only once after baculovirus transduction. The residual baculovirus may be further reduced by simply adding extra washing step(s) or using adequate down-stream purification schema.
- One of the major concerns associated with the use of lentiviral vectors is the probability of generating pathogenic human viruses. To avoid this, the lentivirus genome was separated into four different production plasmids in order to minimize the risk of RCL formation by recombination. No RCL was detected fin the baculovirus-generated lentivirus preparations. p24 levels were not increased after prolonged cultures and no GFP expression was detected in 2.5 weeks after transduction.
- The scalability of virus production for clinical studies remains difficult in adherent cells. Thus, adaptation of lentivirus production to suspension cell cultures would be advantageous. Preliminary results in suspension adapted HEK293 cells in serum-free conditions showed very efficient baculovirus transduction efficacy (95.1% GFP positive cells).
-
- Delenda, 2004. J. Gene Med. 6 Suppl 1: S125-S138.
- Lu, et al. J. Gene Med. 6, 963-973 (2004).
- Follenzi, & Naldini Methods Enzymol. 346, 454-465 (2002).
- Ni, et al. J. Gene Med. 7, 818-834 (2005).
- Cheshenko, et al, Gene Ther. 8, 846-854 (2001).
- Makinen, et al. J. Gene Med. 8, 433-441 (2006).
- Dull, et al. J. Virol. 72, 8463-8471 (1998).
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/862,731 US20160097060A1 (en) | 2007-02-12 | 2015-09-23 | Production of Vectors for Non-Dividing Host Cells |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0702695.8 | 2007-02-12 | ||
GBGB0702695.8A GB0702695D0 (en) | 2007-02-12 | 2007-02-12 | Production of vectors |
PCT/GB2008/000464 WO2008099148A1 (en) | 2007-02-12 | 2008-02-11 | Production of lentiviral vectors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2008/000464 A-371-Of-International WO2008099148A1 (en) | 2007-02-12 | 2008-02-11 | Production of lentiviral vectors |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/862,731 Continuation US20160097060A1 (en) | 2007-02-12 | 2015-09-23 | Production of Vectors for Non-Dividing Host Cells |
US16/681,964 Division US10829785B2 (en) | 2007-02-12 | 2019-11-13 | Nucleic acid application primers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100003746A1 true US20100003746A1 (en) | 2010-01-07 |
Family
ID=37899177
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/522,646 Abandoned US20100003746A1 (en) | 2007-02-12 | 2008-02-11 | Production of Lentiviral Vectors |
US14/862,731 Abandoned US20160097060A1 (en) | 2007-02-12 | 2015-09-23 | Production of Vectors for Non-Dividing Host Cells |
US15/221,265 Abandoned US20170016028A1 (en) | 2007-02-12 | 2016-07-27 | Production of Lentiviral Vectors |
US16/681,964 Active US10829785B2 (en) | 2007-02-12 | 2019-11-13 | Nucleic acid application primers |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/862,731 Abandoned US20160097060A1 (en) | 2007-02-12 | 2015-09-23 | Production of Vectors for Non-Dividing Host Cells |
US15/221,265 Abandoned US20170016028A1 (en) | 2007-02-12 | 2016-07-27 | Production of Lentiviral Vectors |
US16/681,964 Active US10829785B2 (en) | 2007-02-12 | 2019-11-13 | Nucleic acid application primers |
Country Status (8)
Country | Link |
---|---|
US (4) | US20100003746A1 (en) |
EP (1) | EP2118285B1 (en) |
JP (1) | JP2010517554A (en) |
KR (1) | KR20090121320A (en) |
CN (1) | CN101631863A (en) |
AU (1) | AU2008215979B2 (en) |
GB (1) | GB0702695D0 (en) |
WO (1) | WO2008099148A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017059241A1 (en) | 2015-10-02 | 2017-04-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lentiviral protein delivery system for rna-guided genome editing |
WO2017079269A1 (en) | 2015-11-04 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Igf2bp1 and/or igf2bp3 for treatment |
WO2018160491A1 (en) * | 2017-03-01 | 2018-09-07 | Baylor College Of Medicine | Pacs1 enhancement for rev-dependent lentiviral vectors |
US10450574B2 (en) * | 2015-11-24 | 2019-10-22 | Glaxosmithkline Intellectual Property Development Limited | Transient transfection method for retroviral production |
CN112961841A (en) * | 2021-03-03 | 2021-06-15 | 上海佐润生物科技有限公司 | Packaging method for rapidly obtaining high-titer lentiviruses |
WO2022051555A2 (en) | 2020-09-03 | 2022-03-10 | Rampart Bioscience, Inc. | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013535693A (en) * | 2010-08-12 | 2013-09-12 | クロンテック・ラボラトリーズ・インコーポレーテッド | Lateral flow assay for non-diagnostic analytes |
FR2978456B1 (en) * | 2011-07-27 | 2015-02-20 | Genethon | BACULOVIRAL SYSTEM FOR THE EXPRESSION OF A GENE THERAPEUTIC VECTOR |
AU2012342355B2 (en) * | 2011-11-24 | 2017-10-12 | Genethon | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
ES2959326T3 (en) * | 2015-11-24 | 2024-02-23 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
GB201609354D0 (en) * | 2016-05-26 | 2016-07-13 | Glaxosmithkline Ip Dev Ltd | Transient transfection method for retroviral production |
CN106198969A (en) * | 2016-06-27 | 2016-12-07 | 武汉思安医疗技术有限公司 | The concentration detection kit of a kind of lentivirus titers and concentration detection method |
GB201706121D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
JP2022551753A (en) * | 2019-10-16 | 2022-12-13 | カリヴィル イムノセラピューティクス, インコーポレイテッド | Producer virus for generating retroviruses in situ |
IL308018A (en) | 2021-04-30 | 2023-12-01 | Kalivir Immunotherapeutics Inc | Oncolytic viruses for modified mhc expression |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6099847A (en) * | 1997-05-15 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric Gag pseudovirions |
US6338962B1 (en) * | 1996-09-11 | 2002-01-15 | The General Hospital Corporation | Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell |
US6387670B1 (en) * | 1996-11-22 | 2002-05-14 | Aventis Pharma, S.A. | Method for producing recombinant virus |
US20030082789A1 (en) * | 2001-08-02 | 2003-05-01 | Didier Trono | Methods and compositions relating to improved lentiviral vector production systems |
US20030147907A1 (en) * | 1997-12-22 | 2003-08-07 | Kingsman Alan John | Retroviral vectors |
US6863884B2 (en) * | 2002-05-01 | 2005-03-08 | Cell Genesys, Inc. | Pseudotyped retroviral vectors |
US20060199266A1 (en) * | 2004-08-12 | 2006-09-07 | Vectorcore A Co., Ltd. | CAEV-based vector systems |
US7416890B2 (en) * | 2002-09-25 | 2008-08-26 | Osaka Industrial Promotion Organization | Baculovirus vector, method of producing thereof and method of gene transfer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM405794A0 (en) * | 1994-02-23 | 1994-03-17 | University Of Queensland, The | A process for producing viruses or viral proteins |
GB9711578D0 (en) * | 1997-06-04 | 1997-07-30 | Oxford Biomedica Ltd | Novel retroviral vector production systems |
WO2000066759A1 (en) * | 1999-04-29 | 2000-11-09 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
BRPI0514438A (en) * | 2004-08-16 | 2008-06-10 | Smithkline Beecham Corp | compound, pharmaceutical composition, use of a compound, method for treating or prophylaxis of a chemokine receptor modulated condition or disease, and process for preparing the compound |
BRPI0504945B8 (en) * | 2005-10-31 | 2022-08-02 | Fundacao Oswaldo Cruz | METHOD FOR PRODUCTION OF RECOMBINANT FLAVIVIRUS CONTAINING NUCLEOTIDE SEQUENCES ENCODING A HETEROLOGOUS PROTEIN, DNA CONSTRUCT, FLAVIVIRUS, AND, VACCINE COMPOSITION TO IMMUNIZE AGAINST FLAVIVIRUS AND/OR OTHER PATHOGENS. |
-
2007
- 2007-02-12 GB GBGB0702695.8A patent/GB0702695D0/en not_active Ceased
-
2008
- 2008-02-11 EP EP08709361.3A patent/EP2118285B1/en active Active
- 2008-02-11 AU AU2008215979A patent/AU2008215979B2/en active Active
- 2008-02-11 US US12/522,646 patent/US20100003746A1/en not_active Abandoned
- 2008-02-11 WO PCT/GB2008/000464 patent/WO2008099148A1/en active Application Filing
- 2008-02-11 JP JP2009548742A patent/JP2010517554A/en active Pending
- 2008-02-11 CN CN200880004377A patent/CN101631863A/en active Pending
- 2008-02-11 KR KR1020097019060A patent/KR20090121320A/en not_active Application Discontinuation
-
2015
- 2015-09-23 US US14/862,731 patent/US20160097060A1/en not_active Abandoned
-
2016
- 2016-07-27 US US15/221,265 patent/US20170016028A1/en not_active Abandoned
-
2019
- 2019-11-13 US US16/681,964 patent/US10829785B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6338962B1 (en) * | 1996-09-11 | 2002-01-15 | The General Hospital Corporation | Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell |
US6387670B1 (en) * | 1996-11-22 | 2002-05-14 | Aventis Pharma, S.A. | Method for producing recombinant virus |
US6099847A (en) * | 1997-05-15 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric Gag pseudovirions |
US20030147907A1 (en) * | 1997-12-22 | 2003-08-07 | Kingsman Alan John | Retroviral vectors |
US20030082789A1 (en) * | 2001-08-02 | 2003-05-01 | Didier Trono | Methods and compositions relating to improved lentiviral vector production systems |
US6863884B2 (en) * | 2002-05-01 | 2005-03-08 | Cell Genesys, Inc. | Pseudotyped retroviral vectors |
US7416890B2 (en) * | 2002-09-25 | 2008-08-26 | Osaka Industrial Promotion Organization | Baculovirus vector, method of producing thereof and method of gene transfer |
US20060199266A1 (en) * | 2004-08-12 | 2006-09-07 | Vectorcore A Co., Ltd. | CAEV-based vector systems |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017059241A1 (en) | 2015-10-02 | 2017-04-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lentiviral protein delivery system for rna-guided genome editing |
WO2017079269A1 (en) | 2015-11-04 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Igf2bp1 and/or igf2bp3 for treatment |
US10450574B2 (en) * | 2015-11-24 | 2019-10-22 | Glaxosmithkline Intellectual Property Development Limited | Transient transfection method for retroviral production |
WO2018160491A1 (en) * | 2017-03-01 | 2018-09-07 | Baylor College Of Medicine | Pacs1 enhancement for rev-dependent lentiviral vectors |
WO2022051555A2 (en) | 2020-09-03 | 2022-03-10 | Rampart Bioscience, Inc. | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
CN112961841A (en) * | 2021-03-03 | 2021-06-15 | 上海佐润生物科技有限公司 | Packaging method for rapidly obtaining high-titer lentiviruses |
Also Published As
Publication number | Publication date |
---|---|
GB0702695D0 (en) | 2007-03-21 |
WO2008099148A1 (en) | 2008-08-21 |
JP2010517554A (en) | 2010-05-27 |
EP2118285B1 (en) | 2013-07-03 |
AU2008215979B2 (en) | 2012-03-08 |
US10829785B2 (en) | 2020-11-10 |
EP2118285A1 (en) | 2009-11-18 |
US20170016028A1 (en) | 2017-01-19 |
US20160097060A1 (en) | 2016-04-07 |
AU2008215979A1 (en) | 2008-08-21 |
CN101631863A (en) | 2010-01-20 |
US20200071725A1 (en) | 2020-03-05 |
KR20090121320A (en) | 2009-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10829785B2 (en) | Nucleic acid application primers | |
Olsen | Gene transfer vectors derived from equine infectious anemia virus | |
Iwakuma et al. | Self-inactivating lentiviral vectors with U3 and U5 modifications | |
Blesch | Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer | |
Howarth et al. | Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells) | |
US10450574B2 (en) | Transient transfection method for retroviral production | |
US20160230191A1 (en) | Retroviral vectors | |
ES2627445T3 (en) | Lentivirus vector particles resistant to complement inactivation | |
EP2761011B1 (en) | Use of non-subtype b gag proteins for lentiviral packaging | |
US20030207438A1 (en) | Pseudotyped retroviral vectors | |
Berg et al. | Rapid establishment of stable retroviral packaging cells and recombinant susceptible target cell lines employing novel transposon vectors derived from Sleeping Beauty | |
US9840720B2 (en) | Materials and methods relating to packaging cell lines | |
US20220204946A1 (en) | Modified envelope glycoproteins for retroviridae viral vector pseudotyping and process for obtaining it | |
Zufferey et al. | Production of high‐titer lentiviral vectors | |
Molina et al. | Mapping of the bovine immunodeficiency virus packaging signal and RRE and incorporation into a minimal gene transfer vector | |
CA3183599A1 (en) | Compositions and methods for producing stable viral vector producer cells for cell and gene therapy | |
WO2001092506A1 (en) | Siv derived lentiviral vector systems | |
US11965173B2 (en) | Plasmid system | |
US20030134817A1 (en) | SIV derived lentiviral vector systems | |
LLC | Development and Optimization of a High Titer Recombinant Lentivirus System | |
Ngai et al. | Production of lentivirus carrying green fluorescent protein with different promoters for in vitro gene transfer | |
Garoff et al. | Alphavirus-Retrovirus Vectors Henrik Garoff and Kejun Li Karolinska Institutet, Dept. of Biosciences at Novum 141 57 HUDDINGE, Sweden | |
Follenzi et al. | HIV-based vectors | |
Kafri | Gene Delivery by Lentivirus Vectors | |
Brady et al. | High-Titer Human Immunodeficiency Virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARK THERAPEUTICS LTD., UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LESCH, HANNA P.;AIRENNE, KARI J.;YIA-HERTTUALA, SEPPO;REEL/FRAME:023115/0455 Effective date: 20090603 |
|
AS | Assignment |
Owner name: ARK THERAPEUTICS LTD., UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AIRENNE, KARI J.;LESCH, HANNA P.;YLA-HERTTUALA, SEPPO;REEL/FRAME:040901/0241 Effective date: 20090603 Owner name: TRIZELL LTD, UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:FINVECTOR VISION THERAPIES LTD;REEL/FRAME:040901/0335 Effective date: 20160712 Owner name: FINVECTOR VISION THERAPIES LTD, UNITED KINGDOM Free format text: CHANGE OF NAME;ASSIGNOR:ARK THERAPEUTICS LTD.;REEL/FRAME:041304/0595 Effective date: 20130426 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: PHARMACEUTICAL PATENT ATTORNEYS, LLC, NEW JERSEY Free format text: SECURITY INTEREST;ASSIGNOR:TRIZELL LTD.;REEL/FRAME:054775/0546 Effective date: 20090106 |
|
AS | Assignment |
Owner name: TRIZELL LTD., F/K/A FINVECTOR LTD. F/K/A ARK THERAPEUTICS LTD., ENGLAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:PHARMACEUTICAL PATENT ATTORNEYS, LLC;REEL/FRAME:058826/0044 Effective date: 20220124 |